EBV-Associated Cancers
Targeted therapeutics for EBV-driven malignancies including nasopharyngeal carcinoma and certain lymphomas.
Target
Epstein-Barr Virus
Solid Tumors & Oncology
Engineered Chimeric Antigen Receptor (CAR) T-cell therapy designed to target and eliminate HER2-positive solid tumor cells with enhanced specificity.
Target
Human Epidermal Growth Factor Receptor 2 (HER2)
Hematologic Malignancies
Next-generation CD20-targeted CAR-T immunotherapy developed for the treatment of B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Target
CD20 Antigen
CNS & Neurodegenerative Disorders
Adeno-associated virus (AAV) gene therapy engineered for the co-delivery of both the GLP-1 receptor and its agonist to the central nervous system to ensure robust signaling and efficacy.
Target
GLP-1 Receptor & Agonist
Learn more about our pipeline and collaboration opportunities.
Contact Our Team